Perspective Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGPerspective Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 17), showing significant lag compared to the market leaders. Investors should exercise caution due to high volatility (108% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.12 | +13.95% | ABOVE |
| 50 SMA | $3.65 | -2.82% | BELOW |
| 100 SMA | $4.23 | -16.03% | BELOW |
| 150 SMA | $3.72 | -4.68% | BELOW |
| 200 SMA | $3.59 | -1.04% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CATX in an uptrend right now?
CATX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CATX overbought or oversold?
CATX's RSI (14) is 37. The stock is in neutral territory, neither overbought nor oversold.
Is CATX outperforming the market?
CATX has a Relative Strength (RS) Rating of 17 out of 99. CATX is currently lagging the broader market.
Where is CATX in its 52-week range?
CATX is trading at $3.55, which is 58% of its 52-week high ($6.16) and 38% above its 52-week low ($1.96).
How volatile is CATX?
CATX has a Beta of 1.03 and 52-week volatility of 108%. It's more volatile than the S&P 500 - expect bigger swings.